Recombinant DLL4 Protein, Human
Recombinant Proteins
The human DLL4 (NP_061947.1) (Met1-Pro524) was expressed with five amino acids (DDDDK) at the C-terminus
The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa.
Formulation:
The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa.
Source:
HEK293 Cells
Usage:
Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Recombinant DLL4 Protein, Human
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog Number: BT-203269
Molecular Weight: The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa.
Formulation: Recombinant DLL4 Protein was lyophilized from sterile PBS, pH 7.4.1
Source: HEK293 Cells
| Product Name | Recombinant DLL4 Protein, Human |
|---|---|
| Molecular Weight | The recombinant human DLL4 consists of 504a.a and predicts a molecular weight of 55 kDa. |
| AA Sequence | Met1-Pro524 |
| Bioactivity | Measured by the ability of the immobilized protein to enhance BMP2-induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. The ED50 for this effect is typically 4-20 µg/mL in the presence of 500 ng/mL recombinant human BMP2. |
| Endotoxin | < 1.0 EU per μg protein as determined by the LAL method |
| Formulation | Recombinant DLL4 Protein was lyophilized from sterile PBS, pH 7.4.1 |
| Host Species | Homo sapiens (Human) |
| Description | The human DLL4 (NP_061947.1) (Met1-Pro524) was expressed with five amino acids (DDDDK) at the C-terminus |
| Product Background | Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy. |
| Product Memo | Delta-like 4 Protein, Human;hdelta2 Protein, Human |
| Product Type | Recombinant Protein |
| Purity | Greater than 95% as determined by SDS-PAGE. |
| Source | HEK293 Cells |
| Storage | Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Terminal | Ser 27 |
| Usage | Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use |
| Last Modified | Aug 20 2021 |